



Hanna K. Gaggin, MD, Massachusetts General Hospital and Harvard Medical School

Biomarkers — I may be biased because it's one of my research areas. Also, personalized medicine and minimally invasive procedures.



Parag Joshi, MD, University of Texas Southwestern Medical Center

Lipid management and coronary imaging, visceral fat management and HF with preserved ejection fraction.




John D. Groarke, MD, Brigham and Women's Hospital and Harvard Medical School

Clinical studies to understand true CV risk associated with cancer therapies, and interventions to mitigate this risk.




R. Kannan Mutharasan, MD, Northwestern University Feinberg School of Medicine

Behavioral change and modification. We have 90% of the tools we need to prevent CV morbidity like coronary disease, stroke and HF. However, we are very lacking in how to empower people to make good health decisions. Our public policy is not fully geared toward living a healthy lifestyle by default. Simple measures can have big impact. The future is in smart public policy that supports the health of the population.



Steven M. Domsy, MD, Main Line Health System

Left ventricular assist devices over the next 20 years. They are getting smaller and better, and may become an alternative to transplant for more people, which is especially important given the short supply of organs.



Michael Massoomi, MD, University of Florida, Gainesville

Continued advancements in percutaneous treatments such as transcatheter aortic valve replacement, as we are reducing the need for high-risk open surgical procedures. Also, the use of technology in medicine is soaring and I believe it will continue to do so. We need to find ways to embrace and incorporate modern devices into our clinical practice, both to provide better care and to deliver it more efficiently.



Parikshit Sharma, MD, MPH, FACC, Rush University Medical Center

Health care outcomes and utilization. Looking to newer techniques that can improve patient outcomes and minimize health care expenditure.



Ty Gluckman, MD, Providence St. Vincent Medical Center

Research in novel lipid-lowering therapies, direct oral anticoagulants and percutaneous treatment options for valvular heart disease.



Erin D. Michos, MD, MHS, Johns Hopkins School of Medicine

Cost-effectiveness. We have a lot of potentially new and exciting therapies (eg, PCSK9 inhibitors) and interventions (eg, mitral valve clip), but cost-effectiveness data for high-end therapeutics are sorely needed.




Matthew A. Cavender, MD, MPH, University of North Carolina

Population management and risk prediction, and using predictive modeling to determine risks and benefits for therapies.




Joshua W. Knowles, MD, Stanford University

In the near future, I think it is probably big data; a priority should be deconvoluting large amounts of data to make meaningful observations that improve identification, diagnosis and treatment. New, "opportunistic" designs for clinical trials will be important. New drug delivery methods like small interfering RNA will be important in next 10 years (eg, inclisiran).



Ki Park, MD, University of Florida, Gainesville

Structural interventions and women's CV health.



Seth S. Martin, MD, MHS, FACC, FAHA, Johns Hopkins School of Medicine

Prevention, because it's what everyone needs to do. We need to do a better job turning off the faucet; we can't keep mopping up the floor.



Mintu Turakhia, MD, MAS, Stanford University

Pragmatic trials, trials of health care delivery, digital health and artificial intelligence.



Chris Longenecker, MD, University Hospitals Case Medical Center

Implementation science — bridging the "know-do" gap. We have so much evidence of what to do in cardiology, but how to create better uptake of evidence-based therapies in daily practice is poorly understood.



Sanjeev Bhavnani, MD, Scripps Clinic

There are several, of which digital health, big data and precision medicine will have the largest impacts for CV transformation.



Yuli Y. Kim, MD, University of Pennsylvania and Children's Hospital of Philadelphia

Transcatheter valve procedures or minimally invasive procedures, as well as device therapy.